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AIM: To evaluate the performance of FibroMeter combined to the first generation
tests aspartate aminotransferase-to-platelet ratio index (APRI) or Forns index to
assess significant fibrosis in chronic hepatitis C (CHC).
METHODS: First generation tests APRI or Forns were initially applied in a
derivation population from Rio de Janeiro in Brazil considering cut-offs previously
reported in the literature to evaluate significant fibrosis. FibroMeter was
sequentially applied to unclassified cases from APRI or Forns. Accuracy of non-
invasive combination of tests, APRI plus FibroMeter and Forns plus FibroMeter was
evaluated in the Brazilian derivation population. APRI plus FibroMeter combination
was validated in a population of CHC patients from Angers in France. All patients
were submitted to liver biopsy staged according to METAVIR score by experienced
hepatopathologists. Significant fibrosis was considered as METAVIR F ≥ 2. The
fibrosis stage classification was used as the reference for accuracy evaluation of
non-invasive combination of tests. Blood samples for the calculation of serum tests
were collected on the same day of biopsy procedure or within a maximum 3 mo
interval and stored at -70 °C.
RESULTS: Seven hundred and sixty CHC patients were included (222 in the
derivation population and 538 in the validation group). In the derivation population,
the FibroMeter AUROC was similar to APRI AUROC (0.855 0.815, = 0.06) but
higher than Forns AUROC (0.769, < 0.001). The best FibroMeter cut-off to
discriminate significant fibrosis was 0.61 (80% diagnostic accuracy; 75% in the
validation population, = 0.134). The sequential combination of APRI or Forns with
FibroMeter in derivation population presented similar performance compared to
FibroMeter used alone (79% 78% 80%, respectively, = 0.791). Unclassified cases of
significant fibrosis after applying APRI and Forns corresponded to 49% and 54%,
respectively, of the total sample. However, the combination of APRI or Forns with
FibroMeter allowed 73% and 77%, respectively, of these unclassified cases to be
correctly evaluated. Moreover, this combination resulted in a reduction of
FibroMeter requirement in approximately 50% of the entire sample. The stepwise
combination of APRI and FibroMeter applied to the validation population correctly
identified 74% of patients with severe fibrosis (F ≥ 3).
CONCLUSION: The stepwise combination of APRI or Forns with FibroMeter may
represent an accurate lower cost alternative when evaluating significant fibrosis,
with no need for liver biopsy.
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